Immuno-oncology Drugs-Global Market Status and Trend Report 2022-2030

Table Of Contents

Chapter 1 Overview of Immuno-oncology Drugs

1.1 Definition of Immuno-oncology Drugs in This Report
1.2 Commercial Types of Immuno-oncology Drugs
1.2.1 Immune Checkpoint Inhibitors
1.2.2 Immune System Modulators
1.2.3 Cancer Vaccines
1.2.4 Oncolytic Virus
1.2.5 Others
1.3 Downstream Application of Immuno-oncology Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Ambulatory Surgical Centers
1.4 Development History of Immuno-oncology Drugs
1.5 Market Status and Trend of Immuno-oncology Drugs 2022-2030
1.5.1 Global Immuno-oncology Drugs Market Status and Trend 2022-2030
1.5.2 Regional Immuno-oncology Drugs Market Status and Trend 2022-2030
Chapter 2 Global Market Status and Forecast by Regions
2.1 Market Development of Immuno-oncology Drugs 2022-2030
2.2 Production Market of Immuno-oncology Drugs by Regions
2.2.1 Production Volume of Immuno-oncology Drugs by Regions
2.2.2 Production Value of Immuno-oncology Drugs by Regions
2.3 Demand Market of Immuno-oncology Drugs by Regions
2.4 Production and Demand Status of Immuno-oncology Drugs by Regions
2.4.1 Production and Demand Status of Immuno-oncology Drugs by Regions 2022-2030
2.4.2 Import and Export Status of Immuno-oncology Drugs by Regions 2022-2030
Chapter 3 Global Market Status and Forecast by Types
3.1 Production Volume of Immuno-oncology Drugs by Types
3.2 Production Value of Immuno-oncology Drugs by Types
3.3 Market Forecast of Immuno-oncology Drugs by Types
Chapter 4 Global Market Status and Forecast by Downstream Industry
4.1 Demand Volume of Immuno-oncology Drugs by Downstream Industry
4.2 Market Forecast of Immuno-oncology Drugs by Downstream Industry
Chapter 5 Market Driving Factor Analysis of Immuno-oncology Drugs
5.1 Global Economy Situation and Trend Overview
5.2 Immuno-oncology Drugs Downstream Industry Situation and Trend Overview
Chapter 6 Immuno-oncology Drugs Market Competition Status by Major Manufacturers
6.1 Production Volume of Immuno-oncology Drugs by Major Manufacturers
6.2 Production Value of Immuno-oncology Drugs by Major Manufacturers
6.3 Basic Information of Immuno-oncology Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Immuno-oncology Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Immuno-oncology Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
Chapter 7 Immuno-oncology Drugs Major Manufacturers Introduction and Market Data
7.1 Amgen, Inc
7.1.1 Company profile
7.1.2 Representative Immuno-oncology Drugs Product
7.1.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc
7.2 Johnson & Johnson
7.2.1 Company profile
7.2.2 Representative Immuno-oncology Drugs Product
7.2.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.3 Celgene Corporation
7.3.1 Company profile
7.3.2 Representative Immuno-oncology Drugs Product
7.3.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.4 AstraZeneca, Plc
7.4.1 Company profile
7.4.2 Representative Immuno-oncology Drugs Product
7.4.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca, Plc
7.5 Hoffmann-La Roche AG
7.5.1 Company profile
7.5.2 Representative Immuno-oncology Drugs Product
7.5.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Hoffmann-La Roche AG
7.6 Bristol-Myers Squibb
7.6.1 Company profile
7.6.2 Representative Immuno-oncology Drugs Product
7.6.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.7 AbbVie, Inc.
7.7.1 Company profile
7.7.2 Representative Immuno-oncology Drugs Product
7.7.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of AbbVie, Inc.
7.8 Merck & Co.
7.8.1 Company profile
7.8.2 Representative Immuno-oncology Drugs Product
7.8.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Merck & Co.
7.9 Eli Lilly and Company
7.9.1 Company profile
7.9.2 Representative Immuno-oncology Drugs Product
7.9.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.10 Novartis International AG
7.10.1 Company profile
7.10.2 Representative Immuno-oncology Drugs Product
7.10.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Novartis International AG
7.11 Prometheus Therapeutics & Diagnostics
7.11.1 Company profile
7.11.2 Representative Immuno-oncology Drugs Product
7.11.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Prometheus Therapeutics & Diagnostics
7.12 Bavarian Nordic
7.12.1 Company profile
7.12.2 Representative Immuno-oncology Drugs Product
7.12.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Bavarian Nordic
7.13 Pfizer Inc.
7.13.1 Company profile
7.13.2 Representative Immuno-oncology Drugs Product
7.13.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Pfizer Inc.
7.14 ImmunoCellular Therapeutics
7.14.1 Company profile
7.14.2 Representative Immuno-oncology Drugs Product
7.14.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of ImmunoCellular Therapeutics
7.15 Aduro BioTech
7.15.1 Company profile
7.15.2 Representative Immuno-oncology Drugs Product
7.15.3 Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin of Aduro BioTech
7.16 Gilead Sciences Inc.
7.17 Sanofi S.A.
7.18 Celldex Therapeutics
7.19 Galena Biopharma
7.20 EMD Serono, Inc.
7.21 Bio-Rad Laboratories, Inc.
7.22 Incyte
7.23 Lonza Group
7.24 Enzo Biochem, Inc.
7.25 Spring Bank Pharmaceuticals, Inc.
7.26 Agenus Inc.
7.27 Ferring Pharmaceuticals
7.28 Dendreon Corporation
7.29 Avantor, Inc.
7.30 Agilent Technologies Inc
Chapter 8 Upstream and Downstream Market Analysis of Immuno-oncology Drugs
8.1 Industry Chain of Immuno-oncology Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of Immuno-oncology Drugs
9.1 Cost Structure Analysis of Immuno-oncology Drugs
9.2 Raw Materials Cost Analysis of Immuno-oncology Drugs
9.3 Labor Cost Analysis of Immuno-oncology Drugs
9.4 Manufacturing Expenses Analysis of Immuno-oncology Drugs
Chapter 10 Marketing Status Analysis of Immuno-oncology Drugs
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference